Hepatoblastoma Relapse—Findings from the German HB99 Trial and the German Liver Tumor Registry
Survival rates for HB patients have improved; however, outcomes for patients who relapse remain poor. A retrospective review of information gathered for the HB99 study and the German Liver Tumor Registry identified 25 relapse patients (6.9%, 25/362). The median time from initial diagnosis to first r...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/16/4/696 |
| _version_ | 1797298727264714752 |
|---|---|
| author | Rebecca Maxwell Beate Häberle Roland Kappler Dietrich von Schweinitz Mark Rassner Julia von Frowein Irene Schmid |
| author_facet | Rebecca Maxwell Beate Häberle Roland Kappler Dietrich von Schweinitz Mark Rassner Julia von Frowein Irene Schmid |
| author_sort | Rebecca Maxwell |
| collection | DOAJ |
| description | Survival rates for HB patients have improved; however, outcomes for patients who relapse remain poor. A retrospective review of information gathered for the HB99 study and the German Liver Tumor Registry identified 25 relapse patients (6.9%, 25/362). The median time from initial diagnosis to first relapse was 13 months (range: 5–66 months). Two patients relapsed >36 months after initial diagnosis. A total of 68% (17/25) of relapses were metastatic, 24% local, and 8% combined. 67% of local relapses were alive at the last follow-up, in contrast to 53% of metastatic and 0% of combined relapses. At the last follow-up, 73% (8/11) of patients with lung relapses were still alive (0/4 with peritoneal, 1/2 with CNS involvement). A total of 20% of the patients had AFP-negative relapses, 64% of the relapse patients achieved a second complete remission, 69% were still in complete second remission at the last follow-up (median FU of 66 months), and 83% (5/6) of irinotecan-naïve patients who received relapse treatment including irinotecan were in second complete remission at the last follow-up. The 3-year overall survival/event-free survival from relapse was 63%/48% respectively. There is a good chance that HB patients will achieve a second remission despite a first relapse. However, patients who suffer further relapses tend to have a poorer prognosis. |
| first_indexed | 2024-03-07T22:39:11Z |
| format | Article |
| id | doaj.art-edd3819de4264aa088a9b243ad7c01cd |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-07T22:39:11Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-edd3819de4264aa088a9b243ad7c01cd2024-02-23T15:10:38ZengMDPI AGCancers2072-66942024-02-0116469610.3390/cancers16040696Hepatoblastoma Relapse—Findings from the German HB99 Trial and the German Liver Tumor RegistryRebecca Maxwell0Beate Häberle1Roland Kappler2Dietrich von Schweinitz3Mark Rassner4Julia von Frowein5Irene Schmid6Department of Pediatrics, Dr. von Hauner Children’s Hospital, University Hospital, LMU Munich, Lindwurmstraße 4, 80337 Munich, GermanyDepartment of Pediatric Surgery, Dr. von Hauner Children’s Hospital, University Hospital, LMU Munich, 80337 Munich, GermanyDepartment of Pediatric Surgery, Dr. von Hauner Children’s Hospital, University Hospital, LMU Munich, 80337 Munich, GermanyDepartment of Pediatric Surgery, Dr. von Hauner Children’s Hospital, University Hospital, LMU Munich, 80337 Munich, GermanyDepartment of Pediatrics, Dr. von Hauner Children’s Hospital, University Hospital, LMU Munich, Lindwurmstraße 4, 80337 Munich, GermanyDepartment of Pediatrics, Dr. von Hauner Children’s Hospital, University Hospital, LMU Munich, Lindwurmstraße 4, 80337 Munich, GermanyDepartment of Pediatrics, Dr. von Hauner Children’s Hospital, University Hospital, LMU Munich, Lindwurmstraße 4, 80337 Munich, GermanySurvival rates for HB patients have improved; however, outcomes for patients who relapse remain poor. A retrospective review of information gathered for the HB99 study and the German Liver Tumor Registry identified 25 relapse patients (6.9%, 25/362). The median time from initial diagnosis to first relapse was 13 months (range: 5–66 months). Two patients relapsed >36 months after initial diagnosis. A total of 68% (17/25) of relapses were metastatic, 24% local, and 8% combined. 67% of local relapses were alive at the last follow-up, in contrast to 53% of metastatic and 0% of combined relapses. At the last follow-up, 73% (8/11) of patients with lung relapses were still alive (0/4 with peritoneal, 1/2 with CNS involvement). A total of 20% of the patients had AFP-negative relapses, 64% of the relapse patients achieved a second complete remission, 69% were still in complete second remission at the last follow-up (median FU of 66 months), and 83% (5/6) of irinotecan-naïve patients who received relapse treatment including irinotecan were in second complete remission at the last follow-up. The 3-year overall survival/event-free survival from relapse was 63%/48% respectively. There is a good chance that HB patients will achieve a second remission despite a first relapse. However, patients who suffer further relapses tend to have a poorer prognosis.https://www.mdpi.com/2072-6694/16/4/696hepatoblastomarelapseAFPirinotecan |
| spellingShingle | Rebecca Maxwell Beate Häberle Roland Kappler Dietrich von Schweinitz Mark Rassner Julia von Frowein Irene Schmid Hepatoblastoma Relapse—Findings from the German HB99 Trial and the German Liver Tumor Registry Cancers hepatoblastoma relapse AFP irinotecan |
| title | Hepatoblastoma Relapse—Findings from the German HB99 Trial and the German Liver Tumor Registry |
| title_full | Hepatoblastoma Relapse—Findings from the German HB99 Trial and the German Liver Tumor Registry |
| title_fullStr | Hepatoblastoma Relapse—Findings from the German HB99 Trial and the German Liver Tumor Registry |
| title_full_unstemmed | Hepatoblastoma Relapse—Findings from the German HB99 Trial and the German Liver Tumor Registry |
| title_short | Hepatoblastoma Relapse—Findings from the German HB99 Trial and the German Liver Tumor Registry |
| title_sort | hepatoblastoma relapse findings from the german hb99 trial and the german liver tumor registry |
| topic | hepatoblastoma relapse AFP irinotecan |
| url | https://www.mdpi.com/2072-6694/16/4/696 |
| work_keys_str_mv | AT rebeccamaxwell hepatoblastomarelapsefindingsfromthegermanhb99trialandthegermanlivertumorregistry AT beatehaberle hepatoblastomarelapsefindingsfromthegermanhb99trialandthegermanlivertumorregistry AT rolandkappler hepatoblastomarelapsefindingsfromthegermanhb99trialandthegermanlivertumorregistry AT dietrichvonschweinitz hepatoblastomarelapsefindingsfromthegermanhb99trialandthegermanlivertumorregistry AT markrassner hepatoblastomarelapsefindingsfromthegermanhb99trialandthegermanlivertumorregistry AT juliavonfrowein hepatoblastomarelapsefindingsfromthegermanhb99trialandthegermanlivertumorregistry AT ireneschmid hepatoblastomarelapsefindingsfromthegermanhb99trialandthegermanlivertumorregistry |